Hence, immunotherapy with DCs loaded with amixture of tumor-specific peptides (hTERT 988Y, Her2/ neu 369VV2V9, Her2/neu689, and PADRE) in combination with cyclophosphamide injections resulted in theabsence of disease symptoms during 36 months in more than 50% of patients withovarian cancer (6/11); the 36-month survival rate was 90% [75]. Here, ERBB2 is linked to cancer.